Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden

American Heart Journal

Volumn 131, Issue 6, 1996, Pages 1145-1148

  Hirsch, Denise R ^a   Mikkola, Katriina M ^b   Marks, Peter W ^a   Fox, Edward A ^a   Dorfman, David M ^a   Ewenstein, Bruce M ^a   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG EMBOLISM; ORAL CONTRACEPTION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029948169     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90089-7     Document Type: Article

References (16)

1. Syverson CJ, Chavkin W, Atrash HK, Rochat RW, Sharp ES, King EG. Pregnancy-related mortality in New York City, 1980 to 1984: causes of death and associated risk factors. Am J Obstet Gynecol 1991;164:603-8.
2. Högberg U, Innala E, Sandström A. Maternal mortality in Sweden, 1980-1988. Obstet Gyneocol 1994;84:240-4.
3. Morrison RB. Obstetrics. In: Goldhaber SZ, ed. Prevention of venous thromboembolism. New York: Marcel Dekker, 1993:445-61.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
5. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-6.
6. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reltsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
7. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. Touchdown PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 1991;19:4008-9.
8. Gustafson TL. TRUE EPISTAT Reference Manual. Richardson, Tex.: Epistat Services, 1994.
9. Epi Info version 1.01b. Atlanta, Ga.: Centers for Disease Control, Epidemiology Office, July 1991.
10. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
11. Ma DDF, Williams BG, Abound MR, Isbister JP. Factor V missense mutation and APC-resistance in patients with venous thromboembolism [Abstract 323]. Blood Suppl 1994;84:84a.
12. Baechamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familiar thrombosis. Br J Haematol 1994;88:219-22.
13. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gyneeol 1995;173:210-3.
14. Cumming AM, Tait RC, Fildes S, Yoong A, Keeny S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995;90:725-7.
15. Vasse M, Leduc O, Borg JY, Chretien MH, Monconduit M. Resistance to activated protein C: evaluation of three functional assays. Thromb Res 1994;1:47-59.
16. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.